Last reviewed · How we verify
iMAB
iMAB is an investigational immunomodulatory antibody designed to enhance anti-tumor immune responses.
iMAB is an investigational immunomodulatory antibody designed to enhance anti-tumor immune responses. Used for Cancer (specific indication under phase 3 evaluation by EORTC).
At a glance
| Generic name | iMAB |
|---|---|
| Also known as | intermittent maximum androgen blockade |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific molecular targets for iMAB variants under EORTC development are not universally documented in public sources, immunomodulatory antibodies in this class typically work by engaging immune checkpoints or activating immune effector cells to promote tumor recognition and destruction. The exact mechanism depends on the specific iMAB variant in phase 3 development.
Approved indications
- Cancer (specific indication under phase 3 evaluation by EORTC)
Common side effects
Key clinical trials
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors (PHASE3)
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (PHASE1)
- Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome (PHASE1)
- 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (PHASE1)
- Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma (PHASE1)
- CMAB vs IMAB in Metastatic Prostate Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iMAB CI brief — competitive landscape report
- iMAB updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI